Misplaced Pages

Lenvervimab (INN; development code GC1102) is a monoclonal antibody that is being investigated for hepatitis B.

This drug is being developed by GC Pharma. As of 2018, lenvervimab is undergoing Phase II/III trials.

References

1. World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
2. Jeong GU, Ahn BY, Jung J, Kim H, Kim TH, Kim W, Lee A, Lee K, Kim JH (2020). "A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants". PLOS ONE. 15 (8): e0236704. Bibcode:2020PLoSO..1536704J. doi:10.1371/journal.pone.0236704. PMC 7425877. PMID 32790777.

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Monoclonal antibodies
• Monoclonal antibody stubs